Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.74B |
$8.02
+1.78%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.73B |
$31.72
-1.67%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.73B |
$21.57
+2.74%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.72B |
$25.57
+5.29%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$2.69B |
$25.51
+6.03%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.63B |
$49.59
-0.36%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.59B |
$46.27
+0.40%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.59B |
$31.73
+1.02%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$2.53B |
$25.06
+1.50%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.53B |
$31.01
-4.20%
|
|
ITGR
Integer Holdings Corporation
Integer is a contract development and manufacturing organization (CDMO) for medical devices, directly providing design, development and manufacturing services to OEMs.
|
$2.52B |
$72.09
+0.92%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.52B |
$28.73
-2.10%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.31B |
$6.24
-1.27%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.20B |
$20.05
+0.78%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$2.15B |
$16.37
+0.55%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.13B |
$33.34
+13.30%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.11B |
$12.13
+0.04%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$2.08B |
$34.74
+0.01%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.08B |
$21.39
-6.69%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$2.05B |
$27.34
+4.43%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.05B |
$31.14
+0.06%
|
|
SRPT
Sarepta Therapeutics, Inc.
Directly develops gene therapies (ELEVIDYS) and other gene therapy programs; gene therapy is Sarepta's core biotech focus.
|
$2.05B |
$20.97
+8.37%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$2.05B |
$35.59
+0.71%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$2.04B |
$40.32
-5.22%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$2.02B |
$39.99
+0.31%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$2.01B |
$2.12
+2.16%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$2.01B |
$7.75
+3.20%
|
|
MESO
Mesoblast Limited
Focus on rare diseases with pediatric SR-aGvHD and other rare indications in the pipeline.
|
$2.00B |
$17.36
+8.09%
|
Showing page 6 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
